242 related articles for article (PubMed ID: 25963886)
1. Acute myeloid leukemia in the vascular niche.
Cogle CR; Bosse RC; Brewer T; Migdady Y; Shirzad R; Kampen KR; Saki N
Cancer Lett; 2016 Oct; 380(2):552-560. PubMed ID: 25963886
[TBL] [Abstract][Full Text] [Related]
2. Wogonoside impedes the progression of acute myeloid leukemia through inhibiting bone marrow angiogenesis.
Lin B; Zhao K; Yang D; Bai D; Liao Y; Zhou Y; Yu Z; Yu X; Guo Q; Lu N
J Cell Physiol; 2019 Feb; 234(2):1913-1924. PubMed ID: 30105796
[TBL] [Abstract][Full Text] [Related]
3. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.
Wang A; Zhong H
Hematology; 2018 Dec; 23(10):729-739. PubMed ID: 29902132
[TBL] [Abstract][Full Text] [Related]
4. [Angiogenesis in patients with hematologic malignancies].
Mesters RM; Padró T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE
Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia.
Vijay V; Miller R; Vue GS; Pezeshkian MB; Maywood M; Ast AM; Drusbosky LM; Pompeu Y; Salgado AD; Lipten SD; Geddes T; Blenc AM; Ge Y; Ostrov DA; Cogle CR; Madlambayan GJ
Leuk Res; 2019 Sep; 84():106180. PubMed ID: 31299413
[TBL] [Abstract][Full Text] [Related]
6. Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.
Brune MM; Stüssi G; Lundberg P; Vela V; Heim D; Manz MG; Haralambieva E; Pabst T; Banz Y; Bargetzi M; Grobholz R; Fehr M; Cogliatti S; Ossenkoppele GJ; Löwenberg B; Rudolf CB; Li Q; Passweg J; Mazzuchelli L; Medinger M; Tzankov A;
Ann Hematol; 2021 May; 100(5):1169-1179. PubMed ID: 33704530
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitizing AML cells by targeting bone marrow endothelial cells.
Bosse RC; Wasserstrom B; Meacham A; Wise E; Drusbosky L; Walter GA; Chaplin DJ; Siemann DW; Purich DL; Cogle CR
Exp Hematol; 2016 May; 44(5):363-377.e5. PubMed ID: 26898708
[TBL] [Abstract][Full Text] [Related]
8. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia.
Xia B; Tian C; Guo S; Zhang L; Zhao D; Qu F; Zhao W; Wang Y; Wu X; Da W; Wei S; Zhang Y
Leuk Res; 2015 Jan; 39(1):92-9. PubMed ID: 25443862
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML).
Kessler T; Koschmieder S; Schliemann C; Crysandt M; Mikesch JH; von Stillfried S; Stelljes M; Pohlen M; Lenz G; Kirsch A; Vehring K; Wardelmann E; Hartmann W; Bormann E; Gerss J; Brümmendorf TH; Müller-Tidow C; Berdel WE
Ann Hematol; 2019 Jun; 98(6):1393-1401. PubMed ID: 30903275
[TBL] [Abstract][Full Text] [Related]
10. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
[TBL] [Abstract][Full Text] [Related]
11. Targeting the microenvironment in acute myeloid leukemia.
Rashidi A; Uy GL
Curr Hematol Malig Rep; 2015 Jun; 10(2):126-31. PubMed ID: 25921388
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
Fiedler W; Mesters R; Tinnefeld H; Loges S; Staib P; Duhrsen U; Flasshove M; Ottmann OG; Jung W; Cavalli F; Kuse R; Thomalla J; Serve H; O'Farrell AM; Jacobs M; Brega NM; Scigalla P; Hossfeld DK; Berdel WE
Blood; 2003 Oct; 102(8):2763-7. PubMed ID: 12843001
[TBL] [Abstract][Full Text] [Related]
13. Role of Microenvironment in Resistance to Therapy in AML.
Tabe Y; Konopleva M
Curr Hematol Malig Rep; 2015 Jun; 10(2):96-103. PubMed ID: 25921386
[TBL] [Abstract][Full Text] [Related]
14. Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia.
Skelding KA; Barry DL; Theron DZ; Lincz LF
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614005
[TBL] [Abstract][Full Text] [Related]
15. The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells.
Brenner AK; Andersson Tvedt TH; Bruserud Ø
Molecules; 2016 Nov; 21(11):. PubMed ID: 27845732
[TBL] [Abstract][Full Text] [Related]
16. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Karp JE; Gojo I; Pili R; Gocke CD; Greer J; Guo C; Qian D; Morris L; Tidwell M; Chen H; Zwiebel J
Clin Cancer Res; 2004 Jun; 10(11):3577-85. PubMed ID: 15173063
[TBL] [Abstract][Full Text] [Related]
17. RNA trafficking by acute myelogenous leukemia exosomes.
Huan J; Hornick NI; Shurtleff MJ; Skinner AM; Goloviznina NA; Roberts CT; Kurre P
Cancer Res; 2013 Jan; 73(2):918-29. PubMed ID: 23149911
[TBL] [Abstract][Full Text] [Related]
18. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network.
Carter BZ; Mak PY; Chen Y; Mak DH; Mu H; Jacamo R; Ruvolo V; Arold ST; Ladbury JE; Burks JK; Kornblau S; Andreeff M
Oncotarget; 2016 Apr; 7(15):20054-67. PubMed ID: 26956049
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem cells and their vascular niche: Do they benefit from each other?
Ping YF; Zhang X; Bian XW
Cancer Lett; 2016 Oct; 380(2):561-567. PubMed ID: 25979233
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor signaling in acute myeloid leukemia.
Kampen KR; Ter Elst A; de Bont ES
Cell Mol Life Sci; 2013 Apr; 70(8):1307-17. PubMed ID: 22833169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
